Results 161 to 170 of about 73,102 (302)

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Hypoxia-Responsive Fluorescent Prodrugs: Self-Reporting Drug Delivery or Activation in Living Systems. [PDF]

Biosensors (Basel)
Hu X, Song X, Qiu Y, Du W.
europepmc   +1 more source

The effect of anti‐seizure medications on exposure to statins: A systematic review and meta‐analysis

Epileptic Disorders, EarlyView.
Abstract Objectives Antiseizure medications (ASMs) can reduce the efficacy of statin treatment, partly due to reduction in statin concentrations. In this systematic review and network meta‐analysis (NMA), we compared the effects of ASMs and the prototypical enzyme inducer rifampin on statin exposure.
Sharon Valiyev Huino, Hagar Cohen, Bruria Hirsh Raccah, Tomer Ben‐Shushan, Ilan Matok, Sara Eyal   +5 more
wiley   +1 more source

The Evolving Landscape of Hepatocellular Carcinoma Therapy: From Conventional Modalities to TME-Responsive Prodrug Design Strategies. [PDF]

Drug Des Devel Ther
Chen J, Yan H, Wang H, Li H, Wang Z, Ding Q, Zhu YZ.   +6 more
europepmc   +1 more source

Concomitant Use of Proton Pump Inhibitors and Survival Outcomes in Patients Receiving Adjuvant Chemotherapy for Stage III Colon Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Proton pump inhibitors (PPIs) are commonly prescribed in patients with cancer. Prior studies suggest concomitant PPI use may reduce the efficacy of oral capecitabine through impaired absorption, with no interaction expected with intravenous 5‐fluorouracil (5‐FU). Using the Australian Comprehensive Cancer Outcomes and Research Database (ACCORD),
Matthew Loft, Vinoja Ganeshanathan, Rachel Wong, Shehara Mendis, Matthew Croxford, Ian T. Jones, Grace Gard, Sue‐Anne McLachlan, Jeanne Tie, Lucy Gately, Peter Gibbs   +10 more
wiley   +1 more source

A Synergistic Approach Using a ROS-Responsive Lipid-Based Prodrug for Liposomal Delivery of Doxorubicin. [PDF]

Bioconjug Chem
Smith BE, Lou J, Phillips MA, Sagar R, Qualls M, McBee DP, Turner RF, Ullah M, Baccile JA, Best MD.   +9 more
europepmc   +1 more source

Cysteine Peptidases in Antitumor Immunity: Unraveling Antigen‐Presenting Cell Regulation and Therapeutic Potential

iMetaMed, EarlyView.
This review systematically summarizes the central role of cysteine peptidases in modulating antigen‐presenting cell (APC) function and antitumor immune responses, highlighting their critical significance in overcoming tumor immune evasion. Current research has established that cysteine peptidase subtypes, including cathepsins B, S, L, and X, exert ...
Yimao Wu, Xiaoyan Chen, Zichang Chen, Yalun Liang, Gokhan Zengin, Qian Zhang, Wenlong Sun, Meng‐Yao Li   +7 more
wiley   +1 more source

From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics. [PDF]

Signal Transduct Target Ther
Loy CA, Gu Y, Kim SC, Mohagheghi MV, Trask NB, Suarez-Pizarro M, Wagar LE, Benavente CA, Trader DJ.   +8 more
europepmc   +1 more source

ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential

iNew Medicine, EarlyView.
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang, Xinyan Li, Honglu Shi, Gaolei Song, Zhifu Xie, Jingya Li   +5 more
wiley   +1 more source

A Long-Acting Farnesoid X Receptor (FXR) Agonist Prevents Fibrosis. [PDF]

Biomolecules
Sultana A, Bybee G, Pathania AS, Wang W, Thai Hoang Le N, Hanson BW, Bauer CD, Mosley DD, Gendelman HE, Cohen SM, Wyatt TA, Poluektova LY, Edagwa BJ, Osna NA.   +13 more
europepmc   +1 more source